Ben Popken @bpopken
British drugmaker GlaxoSmithKline and German biopharma company CureVac announced striking $180 million deal to develop “next-generation” mRNA covid-19 vaccines that target several variants at once – aiming for 2022, per GSK’s earnings released today. — PolitiTweet.org